Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dare Bioscience Inc (DARE)

Dare Bioscience Inc (DARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,015
  • Shares Outstanding, K 16,683
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,260 K
  • 60-Month Beta 1.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 32.14
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.70
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/12/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +40.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7500 +20.00%
on 03/19/20
1.1800 -23.73%
on 03/10/20
-0.1200 (-11.76%)
since 03/09/20
3-Month
0.7500 +20.00%
on 03/19/20
2.2200 -59.46%
on 01/13/20
+0.0600 (+7.14%)
since 01/09/20
52-Week
0.6902 +30.40%
on 11/14/19
2.2200 -59.46%
on 01/13/20
-0.1600 (-15.09%)
since 04/09/19

Most Recent Stories

More News
Dare Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene(R)

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced it received a Notice of Award of $730,722 in a grant supporting the Ovaprene(R) postcoital test (PCT) clinical...

DARE : 0.9000 (+2.69%)
Dare Bioscience Reports 2019 Financial Results and Provides a Company Update

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the year ended December 31, 2019 and provided a company update.

DARE : 0.9000 (+2.69%)
Dare Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on March 30, 2020, to review...

DARE : 0.9000 (+2.69%)
Dare Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis

DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit after a single administration in an investigator-initiated proof of concept study, which is higher than the...

DARE : 0.9000 (+2.69%)
Dare Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced the presentation of positive findings from a previously reported investigational study that used thermography...

DARE : 0.9000 (+2.69%)
Dare Bioscience to Present at the Cowen 40th Annual Health Care Conference

Dare Bioscience, Inc.(NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the Cowen 40 Annual Health...

DARE : 0.9000 (+2.69%)
Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company's Board of Directors since August 2018, has been named interim Chief Executive Officer, effective...

STIM : 1.9600 (+10.73%)
DARE : 0.9000 (+2.69%)
ANIK : 32.83 (+6.21%)
Dare Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, announced that it has been notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum...

DARE : 0.9000 (+2.69%)
Dare Bioscience to Present at the 2020 BIO CEO & Investor Conference

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the BIO CEO & Investor...

DARE : 0.9000 (+2.69%)
Dare Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, announced that it was notified by the Nasdaq Office of General Counsel that the Company regained compliance with the minimum...

DARE : 0.9000 (+2.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade DARE with:

Business Summary

Dare Bioscience, Inc. is a healthcare company. It involved in the development and commercialization of products in women's reproductive health. Dare Bioscience, Inc., formerly known as Cerulean Pharma Inc., is based in SAN DIEGO.

See More

Key Turning Points

2nd Resistance Point 0.9665
1st Resistance Point 0.9333
Last Price 0.9000
1st Support Level 0.8534
2nd Support Level 0.8067

See More

52-Week High 2.2200
Fibonacci 61.8% 1.6356
Fibonacci 50% 1.4551
Fibonacci 38.2% 1.2746
Last Price 0.9000
52-Week Low 0.6902

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar